Patients with rectal cancer often need a permanent colostomy or suffer from LARS syndrome, both of which can significantly reduce quality of life. At University Hospital Tübingen, radiation oncologist Prof. Dr. med. Cihan Gani and his team are working to change that with the MARS (MR Adaptive Dose-Escalated Radiotherapy for Rectal Sparing) trial, where they are using Elekta Unity MR-Linac to deliver a precise high-dose boost alongside conventional chemoradiation to increase clinical complete response rates and help more patients avoid surgery.

Tune in to hear Prof. Gani talk about his own journey from first hearing about MR-guided radiotherapy (MRgRT) to now leading the MARS trial, where he’s using MR-adaptive dose-escalated radiation therapy to redefine care for rectal cancer.